[Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience].
To evaluate the efficacy and toxicity of campto (CPT-11) monotherapy or combined with 5Fu + leucovorin (CF) in advanced large intestinal cancer. 186 such patients were divided into campto monotherapy group and CPT-11 plus 5Fu + CF [De Gramont (DGM) or Mayo protocal] groups. The mean dose of CPT-11 was 270 mg/m(2) alone in the monotherapy group and 150 mg/m(2) in the combination group. Campto was given as iv infusion in no less than 30-minutes. 186 patients were eligible for response evaluation. The response rates were 27.9% in the monotherapy group, 32.7% in CPT-11 + DGM and 27.3% in CPT-11 + Mayo group. For 55 untreated patients, the response rates of monotherapy, Campto + DGM and Campto + Mayo regime groups were 33.3%, 28.9% and 50.0%. For 131 treated patients, they were 26.4%, 34.8% and 22.2%, respectively. The toxicities of the whole group were 16.0% cholinergic syndrome, 51.9% delayed diarrhea and 19.8% leucopenia. There were 2 treatment-related deaths. The efficacy and toxicities of campto are similar as compared with the reports by other investigators.